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OBJECTIVES: To determine the possible association of serum 25-hydroxyvitamin D (25OHD) levels with disease
activity and respiratory infection in granulomatosis with polyangiitis patients during two different periods:
winter/spring and summer/autumn.
METHODS: Thirty-two granulomatosis with polyangiitis patients were evaluated in the winter/spring, and the
same patients (except 5) were evaluated in summer/autumn (n=27). The 25OHD levels were measured by radio-
immunoassay. Disease activity was assessed by the Birmingham Vasculitis Activity Score Modified for Wegener’s
Granulomatosis (BVAS/WG) and antineutrophil cytoplasmic antibody (ANCA) positivity. Respiratory infection
was defined according the Centers for Disease Control and Prevention criteria.
RESULTS: 25OHD levels were lower among patients in winter/spring than in summer/autumn (32.31±13.10 vs.
38.98±10.97 ng/mL, p=0.04). Seven patients met the criteria for respiratory infection: 5 in winter/spring and 2 in
summer/autumn. Patients with respiratory infection presented lower 25OHD levels than those without infection
(25.15±11.70 vs. 36.73±12.08 ng/mL, p=0.02). A higher frequency of low vitamin D levels (25OHDo20 ng/mL)
was observed in patients with respiratory infection (37.5% vs. 7.8, p=0.04). Serum 25OHD levels were com-
parable between patients with (BVAS/WGX1 plus positive ANCA) and without disease activity (BVAS/WG=0 plus
negative ANCA) (35.40±11.48 vs. 35.34±13.13 ng/mL, p=0.98).
CONCLUSIONS: Lower 25OHD levels were associated with respiratory infection but not disease activity in
granulomatosis with polyangiitis patients. Our data suggest that hypovitaminosis D could be an important risk
factor for respiratory infection in granulomatosis with polyangiitis patients.
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’ INTRODUCTION
Granulomatosis with polyangiitis (GPA, previously known
as Wegener’s granulomatosis) describes systemic vasculitis of
small vessels that is strongly associated with antineutrophil
cytoplasmic antibodies (ANCAs) directed against proteinase-3.
GPA has many heterogeneous manifestations, especially in the
upper and lower respiratory tracts and kidneys (1). The respi-
ratory tract is frequently affected in GPA, with involvement of
the upper airway or the development of pulmonary disease (2).
Patients with GPA have higher mortality during the first
year of disease due to infection in most cases (3). In clinical
practice, it can be very difficult to differentiate respiratory
tract infection and disease activity in GPA. Airway infec-
tion and disease activity involving the respiratory tract are
clinically very similar. Moreover, airway infection may elicit
disease activity, and disease activity may exacerbate and
perpetuate airway infection in GPA patients (4,5).
Vitamin D, in addition to acting on bone metabolism, acts
as an immunomodulator, participating in innate and adaptive
immune responses. 25-hydroxyvitamin D (25OHD) deficiency
has been associated with disease activity in some autoimmune
diseases, such as systemic lupus erythematosus and rheuma-
toid arthritis (6-8). 25OHD deficiency has also been associated
with infection, particularly by respiratory viruses and myco-
bacteria (9-16).
Therefore, this study aimed to determine the possible asso-
ciation of 25OHD concentrations with disease activity and
respiratory infections in patients with GPA during two dif-
ferent periods: winter/spring and summer/autumn. To the
best of our knowledge, no studies have evaluated vitamin D
serum levels in GPA patients and their association with
disease activity or respiratory infection.DOI: 10.6061/clinics/2017(12)02
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’ MATERIALS AND METHODS
Patient selection
A total of 61 consecutive patients with GPA who regu-
larly attended the outpatient Vasculitis Clinic of the Clinic
Hospital of the University of São Paulo were screened from
January 2011 to December 2013. All patients fulfilled the 1990
American College of Rheumatology (ACR) (17) and 2012
Revised International Chapel Hill Consensus criteria for the
classification of GPA (18). Twenty-nine of these patients met
the exclusion criteria due to the presence of other ANCA-
associated diseases, autoimmune diseases, or concomitant
non-respiratory infections. Therefore, 32 patients were eval-
uated (Figure 1). Demographic and clinical data, including
race, age, disease duration, clinical manifestations, comor-
bidities, GPA treatment (glucocorticoid and immunosup-
pressive treatments) and vitamin D supplementation, were
obtained through interviews with the patients and medical
chart reviews. GPA was previously divided into clinical
subgroups categorized by disease severity (localized, gen-
eralized and severe) (17).
The study was performed in accordance with the Declara-
tion of Helsinki. All subjects provided written informed
consent before inclusion in the study.
Seasonal variations
Considering that vitamin D concentrations may be influ-
enced by seasonal variations, serum 25OHD levels were
measured during two periods of the year in each patient.
Samples from 32 patients were evaluated in the winter/
spring, and 27 samples from the same patients were evaluated
in the summer/autumn, resulting in a total of 59 samples.
Five patients were lost in the summer/autumn season:
1 patient died in another hospital from supposed pulmonary
septic shock, 1 patient had a diagnosis of septic arthritis,
and 3 patients were lost to follow-up.
Disease activity and damage scores
GPA disease activity was assessed using the Birmingham
Vasculitis Activity Score Modified for Wegener’s Granulo-
matosis (BVAS/WG), an established tool for clinical use and
research that measures disease activity, vasculitis treatment
outcomes, and the prognosis. The BVAS/WGmeasures activity
according to 34 items that are categorized into 9 groups.
The BVAS/WG values range from 0 to 63. Disease activity
was defined as a BVAS/WG score X1, and remission was
defined as a BVAS/WG score of 0 (19). ANCA positivity was
assessed using an indirect immunofluorescence method and
was also used as a parameter of disease activity (20).
The Vasculitis Damage Index (VDI) was used to assess
damage in all patients. The VDI is a validated checklist of
64 items divided into 11 organ-based systems and an ‘other’
category corresponding to potential treatment side effects.
An item of damage was only recorded if it occurred after
the onset of vasculitis and was considered permanent,
defined as persistence for more than 3 months. In patients
with established comorbidities prior to vasculitis, an item
was only recorded if it had deteriorated significantly within
at least 3 months since disease onset (21).
Respiratory infection
Infection of the upper or lower airways was diagnosed
according to the Centers for Disease Control and Preven-
tion (CDC) criteria. Upper respiratory infection (pharyngitis,
laryngitis, epiglottitis and sinusitis) and lower respiratory
infection (pneumonia, bronchitis, tracheobronchitis, bronch-
iolitis and tracheitis) were defined based on clinical, labo-
ratory, imaging and microbiological parameters (22).
Laboratory parameters
Serum 25OHD levels were measured by radioimmunoas-
say (DiaSorin, Stillwater, MN, USA). Vitamin D deficiency
was defined as 25OHD levels less than 20 ng/mL (23), with
25OHD concentrations sub-categorized as o20 ng/mL and
X20 ng/mL.
C-reactive protein (CRP) levels and the erythrocyte sedi-
mentation rate (ESR) were also evaluated because they may
be elevated due to infection and/or disease activity. CRP
was measured using the immunoturbidimetric method,
and levels higher than 5 mg/L were considered abnormal.
The ESR was measured by the Westergren test, with normal
reference values in the first hour as follows: meno15 mm/
h and women o20 mm/h. The white blood cell count
(WBC) was measured in a local laboratory by an automated
cell counter, with normal levels ranging from 4,000 to
11,000/mm3.
Figure 1 - Selection of Granulomatosis with Polyangiitis (GPA) patients.
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Statistical analysis
Statistical analyses were conducted using the Statistical
Package for the Social Sciences (SPSS for Windows, 21.0,
SPSS Inc). The results are presented as the mean ± SD for
continuous variables and as percentages for categorical vari-
ables. Quantitative variables were analyzed with Student’s
T-test (normal distribution) or the Mann-Whitney (non-normal
distribution) test. Differences between categorical variables
were evaluated using the chi-squared or Fisher’s exact test.
Statistical significance was indicated by p values less than
0.05. A receiver operator characteristic (ROC) curve was con-
structed using continuous serum 25OHD levels to identify
a predictive value of 25OHD associated with respiratory
infection.
’ RESULTS
Fifty-three percent of GPA patients were women (n=17),
and 65.6% (n=21) were white, with a mean age of 46.2±
13.1 years. The mean age at diagnosis was 38.5±13.7 years,
and the mean disease duration was 8.9±4.2 years. Most
GPA patients had the generalized disease form (71.8%), and
the localized form was observed in 28.2% of the patients.
Regarding the baseline clinical condition (winter/spring),
12 (37.5%) patients exhibited disease activity by the BVAS/
WG criteria (BVAS/WGX1), and the mean BVAS/WG was
1.37±2.49. Of these, 7 patients had upper airway involve-
ment (58.3%), 5 had ocular involvement (41.6%), 4 had lower
airway involvement (33.3%), 1 had neurological involvement
(8.3%) and 1 had articular involvement (8.3%). The mean
VDI was 5.5±2.3. ANCA positivity was observed in 59.4%
of the patients in the winter/spring and in 70.4% of the
patients in the summer/autumn. At baseline (winter/spring),
24 (75%) patients were using immunosuppressive agents,
24 (75%) were using trimethoprim-sulfamethoxazole, 16 (50%)
were using prednisone and 3 (9.4%) were using rituximab.
Seven patients met the criteria for infection of the upper or
lower airways: 5 in winter/spring and 2 in summer/autumn
(Table 1). The same patient exhibited infection in winter/
spring and subsequently in summer/autumn (patient #4 =
patient #7). We observed 5 cases of tracheobronchitis, 1 case
of pneumonia and 1 case of sinusitis. Table 1 shows the diag-
nostic criteria for respiratory infection. Two patients fulfilled
the criteria for respiratory infection and the BVAS/WG
criteria for respiratory activity simultaneously.
Table 2 shows the treatments applied in patients with
disease activity and respiratory infection. All 7 patients with
respiratory infection, except 1, were using immunosuppres-
sive agents, and 5 were using prednisone (15.7±17.89 mg/
day). No differences regarding prednisone, immunosuppres-
sive agents or rituximab use were observed between GPA
patients with and without infection. Moreover, no differences
were observed relative to treatment in patients with and
without disease activity (Table 2).
No difference in the frequency of respiratory infection
relative to a particular season was observed (data not shown).
Of the 59 samples, 39 (66%) were obtained from patients
who had received vitamin D supplementation (mean 800-
7,000 IU/day). No difference was observed in 25OHD con-
centrations between patients with or without supplementation
(34.87±12.51 vs. 36.31±12.81 ng/mL, p=0.68). However,
25OHD concentrations were significantly lower in patients
in the winter/spring period than in the summer/autumn
period (32.31±13.10 vs. 38.98±10.97 ng/mL, p=0.04).
Table 1 - Respiratory infections in seven patients with Granulomatosis with Polyangiitis (GPA) and their respective BVAS/WG and
serum 25OHD levels.
Patient Infection Infection Criteria Season BVAS BVAS
Criteria
25OHD
ng/mL
Vitamin D
supplementation
1 Pneumonia Fever, cough, dyspnoea, leucocitosis, chest X-ray
(pulmonary infiltrates), positive pleural fluid culture
(Acinetobacter baumanni)
Winter/
spring
0 - 18.52 No
2 Sinusitis Fever, nasal discharge, headache, X-ray with evidence
of infection
Winter/
spring
2 Nasal crusts 25.19 Yes
3 Tracheobronchitis Fever, cough, leucocitosis, chest X-ray without evidence
of pneumonia
Winter/
spring
2 Proptosis 19 Yes
4 Tracheobronchitis Fever, cough, wheeze, increased pulmonar secretion,
chest X-ray without evidence of pneumonia, positive
bronchoalveolar lavage fluid culture (Streptococcus
viridans)
Winter/
spring
3 Neuropathy 37.65 Yes
5 Tracheobronchitis Fever, coagh, leucocitosis, chest X-ray without evidence
of pneumonia
Winter/
spring
0 - 7.48 Yes
6 Tracheobronchitis Fever, cough, wheeze, leucocitosis, chest X-ray without
evidence of pneumonia
Summer/
autumn
2 Hearing
loss
41.55 Yes
7 Tracheobronchitis Fever, cough, wheeze, increased pulmonar secretion,
chest X-ray without evidence of pneumonia
Summer/
autumn
3 Pulmonary 26.68 Yes
BVAS/WG: Birmingham Vasculitis Activity Score Modified for Wegener’s Granulomatosis.
Table 2 - Current treatment in patients with Granulomatosis with Polyangiitis (GPA) with activity disease and respiratory infection.
Disease Activity Respiratory Infection
Activity (n=25) No Activity (n=34) p-values Infection (n=7) No Infection (n=52) p-values
Prednisone, n (%) 15 (60) 11 (32.3) 0.06 5 (71.4) 20 (38.4) 0.12
Immunosuppressive, n (%) 21 (84) 19 (55.8) 0.09 6 (85.7) 34 (65.3) 0.41
Rituximab, n (%) 2 (8) 1 (2.9) 1.00 0 3 (5.7) 1.00
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No differences were observed in the data of GPA patients
between the winter/spring season (n=32) and the summer/
autumn (n=27) relative to the BVAS/WG (1.37±2.49 vs.
1.70±1.81, p=0.28), VDI (5.50±2.25 vs. 5.29±2.30, p=0.36),
WBC (7,435±2,943 vs. 6,711±2,209/mm3, p=0.14), ESR (13.41±
16.94 vs. 13.41±12.94 mm/h, p=0.49) and CRP level (6.00±
10.72 vs. 10.49±23.71 mg/L, p=0.17).
No differences were observed regarding serum 25OHD
levels and disease activity parameters relative to a BVAS/WG
X1 vs. a BVAS/WG=0 (35.48±12.23 vs. 35.25±12.99 ng/mL,
p=0.94), ANCA positivity vs. ANCA negativity (35.73±12.23
vs. 34.68±13.32 ng/mL, p=0.75), high CRP vs. normal CRP
(37.06±13.68 vs. 34.67±12.13 ng/mL, p=0.51) and high ESR
vs. normal ESR (35.06±11.63 vs. 35.51±13.10 ng/mL, p=0.89).
In contrast, patients with a diagnosed respiratory infection
had lower 25OHD concentrations than those without infec-
tion (25.15±11.70 vs. 36.73±12.08 ng/mL, p=0.02). More-
over, a higher frequency of low vitamin D levels (25OHD
o20 ng/mL) was observed in patients with respiratory
infection (37.5% vs. 7.8, p=0.04) (Table 3). ROC curve analysis
indicated that a serum 25OHD level less than 27.9 ng/mL
was associated with respiratory infection, with a sensitivity
of 71.4%, a specificity of 75% and an area under the curve
of 0.769 (Figure 2). For 25OHD levels less than 30 ng/mL,
the sensitivity was 71.4%, and the specificity was 70.2%
or respiratory infection.
’ DISCUSSION
This study evaluated serum 25OHD levels in GPA patients
and demonstrated for the first time that lower serum 25OHD
levels were associated with respiratory infection in these
patients. In fact, vitamin D deficiency has been linked to
bacterial and viral infections, such as influenza, parainfluenza
and respiratory syncytial virus (9-16,24,25). Our study con-
firmed and extended previous findings showing that
25OHD values lower than 20 ng/mL could be associated
with respiratory infection. Epidemiologic studies have
explored the association between seasonal variations in
vitamin D levels and infections. In winter, lower serum
vitamin D levels were associated with a higher incidence
of infections, including septic shock (26), respiratory infec-
tion (27) and influenza (27,28).
Defense against infectious processes appears to be an
extra-skeletal effect of vitamin D. Vitamin D increases the
chemotaxis of inflammatory cells, enhances the phagocytosis
of these cells, and stimulates the production of reactive oxygen
species, leading to the destruction of pathogens. Vitamin D
has also been associated with the direct production of
cathelicidin, a peptide with bactericidal action (12,15,16,29).
Regulation of the vitamin D receptor (VDR) is a mechanism
used to defend against pathogens. However, some pathogens
can evade the immune system by down-regulating VDR
on the surfaces of monocytes and macrophages (30). VDR
is present in most cells of the immune system, especially
lymphocytes, neutrophils, macrophages and dendritic cells,
and suppresses antigen presentation and the activation and
recruitment of Th1 lymphocytes (15,31).
In our study, ROC curve analysis showed that serum
25OHD levels less than 27.9 ng/mL were associated with
respiratory infection. Previous studies have shown that
vitamin D status is associated with the risk of respiratory
infection, especially in healthy individuals with levels below
20 ng/mL (4,5). Subclinical 25OHD deficiency was asso-
ciated with severe lower respiratory tract infection in an
Indian study (10), and clinical vitamin D deficiency was
associated with a 13-fold increased risk of pneumonia in
Ethiopian children (32). A Finnish study with young army
recruits identified an association of 25OHD serum levels
o16 ng/mL with acute respiratory infections and more days
of absence from duty (33). In addition, Cannell et al. com-
piled epidemiological data regarding the association between
seasonal variations in vitamin D levels and influenza and
concluded that a lack of vitamin D during the winter may
correspond to the infectivity of the influenza virus (28).
Table 3 - Respiratory infection (presence or not), values of white
blood cell count, C-reactive protein and erythrocyte sedimenta-
tion rate comparing patients with Granulomatosis with Polyangi-
itis (GPA) with serum levels of 25OHDX 20 ng/mL vs.o 20 ng/mL.
25OHD X 20 ng/mL
(n=51)
25OHD o 20 ng/mL
(n=8)
p-values
Infection 0.04
No 47 (92.2%) 5 (62.5%)
Yes 4 (7.8%) 3 (37.5%)
WBC 0.13
High 3 (5.9%) 2 (25%)
Normal 48 (94.1%) 6 (75%)
CRP 1.00
High 15 (29.4%) 2 (25%)
Normal 36 (70.6%) 6 (75%)
ESR 0.70
High 18 (35.3%) 2 (25%)
Normal 33 (64.7%) 6 (75%)
Respiratory infection by Centers for Disease Control and Prevention
(CDC) criteria.
WBC: White blood cell count (normal values: 4,000 - 11,000/mm3).
CRP: C-reactive protein (high: 45 mg/L).
ESR: Erythrocyte sedimentation rate (high: 415mm for men and 420mm
for women).
Figure 2 - ROC curve analysis for serum 25OHD levels and
respiratory infection in Granulomatosis with Polyangiitis (GPA)
patients. 25OHD concentrations less than 27.9 ng/mL were
predictor of respiratory infection with 71.4% sensitivity and
75% specificity.
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A randomized, double-blind, placebo-controlled trial in
schoolchildren demonstrated that vitamin D supplementa-
tion (1,200 U/day) significantly decreased the incidence of
influenza infection by 42% in the winter (16).
Interestingly, in our study, no association between lower
vitamin D levels and disease activity was observed, although
the association between vitamin D levels and the immune
system has been recognized in the literature. Vitamin D acts
as an immunomodulator of the innate and acquired immune
system, balances proinflammatory and anti-inflammatory
cytokines, decreases the maturation of dendritic cells, reduces
the proliferation of B lymphocytes, increases Th1 and Th17
responses and stimulates Treg cells (13). Poor vitamin D
status is associated with the risk of rheumatologic diseases,
including systemic lupus erythematous, rheumatoid arthritis
and Behc¸et’s disease (7,34). However, no study has demon-
strated an association of disease activity in ANCA-associated
vasculitis with vitamin D serum levels and vitamin D
supplementation.
As expected, our study identified lower serum 25OHD
levels among subjects in the winter/spring period than in the
summer/autumn period, reflecting the relationship between
seasonality and vitamin D serum concentrations (16). Our
patients were evaluated during two different periods, winter/
spring and summer/autumn, but no difference between
disease activity or infection was observed between seasons.
Interestingly, in our study, no associations between infec-
tion or disease activity and CRP, ESR or WBC values were
observed. Although these markers can be altered by certain
conditions, laboratory parameters can also be affected by
glucocorticoid and immunosuppressive treatments (35).
A limitation of this study is that our findings were
restricted to more severe GPA disease because our patients
predominantly had the generalized form of GPA with a
high VDI, indicating greater severity and a higher risk of
mortality (36). Moreover, we applied strict inclusion and
exclusion criteria, and all patients, except for 5, were eval-
uated during two different periods. This study was also very
strict in considering the CDC criteria for respiratory infection
to avoid presumptive diagnoses of infection.
Lower 25OHD levels were associated with respiratory
infection but not disease activity in GPA patients. Our data
suggest that 25OHD hypovitaminosis could be an important
risk factor for respiratory infection in GPA.
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